Modulation of Microbial Composition in Ileostomy Patients

Ileostomy - Stoma Clinical Trial

— INSIDE  

Official title:

Modulation of Small Intestinal Microbial Composition and Activity,Systemic Immune Adaptation and Blood Transcriptional Changes Induced by 2-wks Consumption With 2 Fermented Milk Products;a Randomized,Exploratory,Cross-over,Double Blind,Controlled Study in Ileostomy Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02920294
• Other study ID #: METC 163023
• Status: Completed
• Phase: N/A
• Start date: September 2016
• Est. completion date: November 11, 2017

Study information

• Verified date: July 2018
• Source: Maastricht University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To determine the small intestinal microbiota response in humans to dietary interventions for two consecutive weeks, and to relate this to parameters of intestinal barrier function and immune and metabolic responses in blood, as functional outcome parameters of host physiology

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: November 11, 2017
• Est. primary completion date: November 11, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• • Ileostomy installed at least 3 years prior to participation

• Free of any complications originating from the colectomy procedure for at least 1 yr prior to participation, with the exception of possible skin irritation at the location of the stoma

• BMI from 18 till 28 kg/m2

• Age from 18 till 70 years

• Available for entire study protocol.

• For female: If of child bearing potential, female subjects must be using or complying with methods of contraception (such as oral birth control pills, intra-uterine device, double barrier methods (like condoms and spermicide, etc.)

Exclusion Criteria:

• • History of cardiovascular, respiratory, urogenital, hepatic, haematological / immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurological diseases, allergy, laboratory assessments which might limit participation in or completion of the study protocol, and/or major surgery with the exception of total colectomy, hysterectomy and/or appendectomy.

• Subject with known lactose intolerance or with known or suspected allergy or hypersensitivity to any component of the study product(s) (milk protein for example) + sucrose + rhamnose

• Severe gastrointestinal symptoms. In case of mild gastrointestinal symptoms, the principal investigator and the medically responsible MD will judge eligibility to participate.

• Removal of more than 15 cm of the ileum during or at any moment after the colectomy procedure

• Abdominal surgery interfering with gastrointestinal function, upon judgment of the principal investigator and the medically responsible MD

• Use of medication, including proton pump inhibitors, non-steroidal anti-inflammatory drugs interfering with endpoints (but except oral contraceptives), within 14 days prior to and during participation.

• Consumption of any probiotic or prebiotic supplements or pre- and probiotics containing food products, investigational drugs or participation in any scientific intervention study which may interfere with this study (to be decided by the principal investigator), in the 4 weeks prior to the study and during study participation (E4 PreProbiotics).

• Use of antibiotics in the 4 weeks prior to the start of study and during study participation

• Prohibited use of pro-, pre- or synbiotics during study period and three months prior to start of study. A list with forbidden products will be provided`

• History of any side effects towards intake of pro- or prebiotic supplements of any kind.

Related Conditions & MeSH terms

• Ileostomy - Stoma

Intervention

Dietary Supplement:
• Probiotic 1
Fresh fermented dairy drink containing yoghurt ferments
• Probiotic 2
Fresh fermented dairy drink containing probiotic strain
• Placebo
Acidified dairy drink without ferments

Locations

Country	Name	City	State
Netherlands	Maastricht University Medical Centre	Maastricht	Limburg

Sponsors (1)

Lead Sponsor	Collaborator
Maastricht University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Temporal microbial composition and activity in the small intestine in ileal effluent	The microbiome activity will be determined as a function of the diet by double strand cDNA production and random sequencing of mRNA enriched fractions of total effluent RNA obtained from the effluent samples at the start and end of each intervention period.	2 weeks intervention
Secondary	Small intestinal permeability by a multi sugar test (urinary recovery of test sugars)		2 weeks intervention
Secondary	Gene transcription response in blood by transcriptome patterns.	Transcriptome patterns will be determined in peripheral blood mononuclear cells obtained from blood samples from the participating ileostoma patients	2 weeks intervention
Secondary	The levels of a panel of peripheral blood biomarkers related to immune, metabolic and hormonal status	A panel of biomarkers will be determined in peripheral blood obtained at the start and end of the intervention periods	2 weeks intervention
Secondary	The level of whole blood immune responsiveness to a panel of standardized stimuli ex vivo	Peripheral whole blood immune responsiveness towards a subset of bacterial immune-stimuli will be assessed using the standardized truculture system	2 weeks intervention
Secondary	Morning urine metabolome profiles	The principal analytical methodology employed is mass-spectrometry profiling and can commonly provide reliable quantifications of more than 400 named-metabolites in different body-fluid samples.	2 weeks intervention
Secondary	Peripheral blood metabolome profiles	The principal analytical methodology employed is mass-spectrometry profiling and can commonly provide reliable quantifications of more than 400 named-metabolites in different body-fluid samples.	2 weeks intervention
Secondary	The relative survival of bacterial strains (colony forming unit enumeration on semi-selective culture plates)		2 weeks intervention
Secondary	Short chain fatty acid profiles in ileal effluent		2 weeks intervention
Secondary	Number of participants with Gastrointestinal symptoms by Visual Analogue Scales		2 weeks intervention
Secondary	Occurrence and severity of treatment related adverse events		2 weeks intervention